
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals is a promising biopharmaceutical company with their recent launch of Cardamyst in the US. Along with potential for non-dilutive cash flow and growth, the drug has gained commercial coverage and is being promoted to physicians as a convenient and cost-effective option for treating PSVT and AFib-RVR. However, challenges in achieving desired prescription volume and revenue, as well as uncertainties surrounding the success of their Phase 3 trial for AFib-RVR treatment, make the company's future prospects less clear.
Bears say
Milestone Pharmaceuticals is facing several fundamental challenges, including limited insurance coverage and low investor valuation due to skepticism about the commercial potential of its lead product, Cardamyst. Additionally, the company is currently experiencing operating losses and may require additional capital in the future. Finally, the success of expanding Cardamyst into AFib-RVR treatment depends on the results of ongoing clinical trials and subsequent regulatory approvals, which are uncertain.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares